Breast Augmentation Guide: Options, Risks & Planning

Breast augmentation increases breast volume using implants or transferred fat. Deciding whether to have it involves more than choosing a size: you need to understand the intended change, the limits of the procedure, the proposed implant or fat-transfer plan, the risks, recovery and future care. For implants, the FDA emphasizes that the devices are not lifetime products and that further surgery may be needed. ASPS procedure overview; FDA decision information.

A useful consultation ends with a decision record, not just a preferred photograph. The record in this guide connects what you want to change with the exact proposed treatment, the information supporting it and the practical responsibilities that follow. Use it to identify questions for the clinician; it does not select a device, determine candidacy or replace consent.

Define volume, shape and lift as separate goals

ASPS describes breast augmentation as a way to increase fullness, restore lost volume or address differences in breast size. It also explains that augmentation alone does not correct severe drooping; a breast lift may need to be discussed separately or alongside augmentation. Those are different treatment questions, even when the desired result is described with a single word such as “fuller.” ASPS scope and limitations.

Begin with the situation you want to discuss: your appearance in clothing, volume after a body change, the balance between the breasts or a concern about position. Describe the features you value as well as the ones you would like to change. A goal such as “more fullness while keeping a proportionate appearance in my usual clothes” gives the conversation a purpose without pretending to specify the surgical answer.

Ask the surgeon to separate what the proposed breast augmentation addresses from what it leaves unchanged. If a lift is recommended, request the reasoning, the additional scope and the effect on the quote and recovery plan. Do not assume a larger implant answers a question about position simply because both options change appearance. A clinical assessment is needed to connect your goal to a proposal.

Your goal or concern	Conversation to request	Decision-record field
More volume	How does the proposed method address my goal?	Intended change and limits
Different shape or proportion	Which measurements and features influenced the plan?	Explanation in the clinician’s words
Breast position or drooping	Is a lift part of the discussion, and why?	Separate proposed procedures
Existing asymmetry	What difference may remain after treatment?	Expected limits and follow-up assessment
Avoiding an implanted device	Is fat transfer appropriate to discuss in my case?	Alternative considered and unanswered questions

This is a goal-organizing table, not a treatment comparison with predicted outcomes. Keep the surgeon’s recommendation and your preference in separate fields. When they differ, ask for an explanation rather than changing your written goal to make the disagreement disappear.

Compare the actual options offered for breast augmentation

FDA information distinguishes saline-filled implants, with a silicone shell containing sterile saltwater, from silicone gel-filled implants. Its US approval information lists augmentation in women aged 18 or older for saline implants and 22 or older for silicone gel implants. These are labeling boundaries, not a personalized assessment of whether surgery is appropriate. The FDA advises checking current device labeling for detailed safety information. FDA implant types and approval scope.

Ask for the exact device under discussion, including manufacturer, model, fill, surface and dimensions. “Silicone” is a category, not a complete device identity. Similarly, a description of implant volume does not document every feature of the proposed treatment. Keep any change in the recommended device visible in the record and ask why it changed.

Fat transfer is another method identified in the ASPS breast augmentation overview. If it is being offered, ask for a separate explanation of the proposed procedure, its limits, its recovery and the evidence relevant to your goal. This guide does not use implant-specific monitoring information as if it were a fat-transfer requirement. It also does not present an unsupported numerical comparison of the two methods.

Option under discussion	Information to collect	Avoid this shortcut
Saline implant	Exact model, label, fill and surface; planned placement	Treating a fill category as a complete safety assessment
Silicone gel implant	Exact model, label and monitoring discussion	Assuming appearance alone establishes implant integrity
Fat transfer	Actual operative plan and procedure-specific risks and limits	Applying implant facts to a different procedure
Augmentation with a lift	Separate scope for each operation	Comparing its quote with augmentation alone
No operation at present	The concerns you still want resolved	Treating a consultation as a commitment to surgery

Ask how the clinician arrived at the proposal and which alternatives were considered. The most useful comparison is among plans that could actually address your own task, with their limits stated. A national popularity figure or a promotional description does not answer that question.

Build a device decision record you can keep

The FDA’s risk-communication requirements include a boxed warning, patient decision checklist, device description and patient device card. The checklist is reviewed with the prospective patient and signed by both the patient and the implanting physician. It is intended to support an informed discussion of risks and benefits. FDA labeling and checklist requirements.

Bring an organizer with four sections: goals, proposed device, care obligations and unresolved questions. Leave spaces for the label version, the date you received it and the person who explained it. Do not initial an item merely because the wording looks familiar; ask about anything that does not make sense in the context of your own plan.

In the device section, record both the proposal and, after surgery, the actual device identifiers supplied by the treating team. Store a copy of the device card somewhere you can retrieve it if the original office is unavailable. The FDA’s BIA-ALCL information specifically recommends retaining the manufacturer and model information and explains that operative records can help identify an implant. FDA device-record advice.

For the care section, ask who will provide follow-up, what monitoring is recommended, how to arrange it and what may be billed separately. An appointment reminder without a named care pathway is not a complete plan. If you move or change clinicians, the same record should help explain what device you have and what monitoring has already occurred.

Understand placement and incision discussions

ASPS describes implant placement either beneath the pectoral muscle or behind breast tissue and above that muscle. Its procedure guidance describes incision options including the breast fold, areolar edge and armpit, with the plan depending on factors such as anatomy and the proposed implant. These descriptions introduce the discussion; they do not identify a universally best placement or incision. ASPS operative overview.

Ask the surgeon to draw or explain the proposed arrangement and identify the reason it was chosen for you. Record the incision location, placement description and any additional procedure. If unfamiliar terminology is used, ask how it corresponds to that explanation. A short label on a quote should not be the only record of what is planned.

Also ask what a sizing demonstration or simulation is intended to communicate. Record which features it helps discuss and which questions it cannot settle. Treat an image as part of a conversation, with its stated limitations written down. This guide does not assign a guaranteed appearance to a particular implant volume or translate that volume into a promised bra size.

Put implant risks into distinct categories

The FDA lists concerns including capsular contracture, rupture or deflation, pain, altered sensation and additional surgery. Capsular contracture involves tightening of the tissue capsule around the implant. Silicone rupture can be silent, so appearance or physical examination alone may not reveal it; the FDA describes MRI and, for asymptomatic screening, ultrasound as imaging options. FDA complications and rupture information.

Ask which risks are relevant to the exact device and procedure, how they are described in its label and what would happen if a problem were suspected. A general complication list does not provide a personal probability. Device-specific studies also need their population and duration explained before a percentage can be used meaningfully.

BIA-ALCL is an immune-system lymphoma associated with breast implants, not ordinary breast cancer. FDA guidance says its risk is higher with textured than smooth surfaces and identifies persistent swelling, a mass or pain near the implant as symptoms requiring evaluation. Keep the surface discussion separate from the fill discussion; they are different device characteristics. FDA BIA-ALCL questions and answers.

A separate FDA safety communication describes reports of squamous cell carcinoma and other lymphomas in the implant capsule. It states that the cause, incidence and risk factors for capsule-associated SCC remain unknown. Do not turn the reported cases into an individual percentage or merge them with BIA-ALCL statistics. FDA communication, issued March 8 and updated March 22, 2023.

Patients also report systemic symptoms described as breast implant illness, including fatigue, concentration difficulties and joint or muscle pain. The FDA says the cause and relationship to implants remain uncertain; BII has no specific recognized diagnostic test or criteria. Its passive reporting system cannot establish incidence or causation by itself. Symptoms warrant a clinical conversation, rather than dismissal or a promise that one intervention will resolve them. FDA systemic symptom and reporting limitations.

Plan monitoring before the breast augmentation operation

FDA labeling guidance recommends an initial ultrasound or MRI for asymptomatic silicone gel implant patients five to six years after implantation, followed by screening every two to three years. It distinguishes this from assessment of symptoms or uncertain ultrasound findings. The guidance document was issued September 29, 2020; discuss the current label and your own circumstances with the treating clinician. FDA labeling guidance, rupture-screening section.

Use the recommendation as a question to resolve before surgery: “What monitoring applies to my proposed device, and who will arrange it?” Do not treat a scheduled future screening date as a reason to wait when a new concern arises. FDA patient information advises prompt contact with a clinician about abnormal changes. FDA ongoing-care advice.

Keep a care log that records actual appointments and imaging, the reason for each assessment and where its report is stored. Separate an implant-integrity discussion from your general breast-health care so that you can ask the clinician how each is being addressed. Leave medical interpretation to the care team; the log helps preserve information, not interpret a scan.

Budget for the operation and for future care

ASPS explains that its breast augmentation fee information does not include all costs, such as anesthesia, facilities and other related expenses. It also advises checking insurance terms because cosmetic augmentation and related expenses may be excluded. A surgeon-fee figure is therefore not a complete patient budget or a promise of coverage. ASPS fee and insurance definitions.

Request a dated quote for the exact proposed breast augmentation. Identify whether it includes implants, anesthesia, facility charges, tests, prescriptions, garments and follow-up. If a lift or another procedure is proposed, keep that scope explicit. This guide does not supply a national total or assume that every bundled quote includes the same items.

Budget record	Obtain before committing	Keep separate from
Initial operation	Written included and excluded charges	An undated national fee average
Early follow-up	Visits, supplies and contact arrangements	Assumptions based on another patient’s package
Monitoring	Recommended pathway, possible separate bills and insurer response	A claim that all future care is included
Possible later surgery	Written policy and insurance exclusions	An unsupported lifetime-cost forecast
Practical support	Your own travel, time and help-at-home costs	Clinical charges billed by the practice

Calculate the initial total from confirmed quote items once each. List unknown amounts rather than inventing them. For future care, use categories and actual coverage information, not an arbitrary annual allowance presented as research. The FDA advises planning for possible reoperations and notes that removal or replacement may not be insured. FDA long-term decision considerations.

Organize recovery around your actual responsibilities

ASPS describes postoperative dressings or a support garment, individualized instructions and follow-up. Soreness and swelling can continue beyond the initial recovery period, and activity should increase according to the treating surgeon’s instructions. A calendar borrowed from another patient does not establish when you can return to your own tasks. ASPS recovery overview.

Tell the team about lifting at work, caring for children or other dependents, commuting and exercise. Ask what support you will need for each responsibility and what signs would change the plan. Record the actual instructions given rather than converting “as tolerated” or another phrase into an independent clearance date.

ASPS preparation guidance includes possible testing, medication adjustments and arranging transport and overnight support for outpatient surgery. Discuss medications and smoking or substance use honestly with the surgical team; do not independently change a prescription because of a general online list. ASPS preparation guidance.

Ask who answers after-hours concerns and where an urgent assessment would occur. Keep those arrangements with the device record, the postoperative instructions and the next appointment. If you are travelling, resolve the follow-up location and the plan for an unexpected concern before purchasing the trip.

Evaluate results without losing the original goal

Test whether your decision record is complete

Try this hypothetical exercise before committing to breast augmentation: imagine that you need to explain the proposal to a new clinician without the original brochure. Can you identify the method being proposed, the exact device if there is one, the additional procedures and the follow-up arrangements? If not, the record still has gaps to resolve. This exercise describes no actual patient and predicts no outcome.

Start with the goal. If the proposal says only “larger,” return to your original concerns about clothing, proportion, asymmetry or position. Ask which are included in the breast augmentation discussion and which require a different assessment. If a lift has been added since the first visit, record why, whether it is part of the same proposal and what questions remain about it. The decision record should reflect a change in scope rather than quietly replacing the earlier plan.

Next inspect the device information. If you have been shown several options, separate “discussed” from “recommended” and “chosen.” A list of brochures does not identify the selected breast augmentation implant. Ask the team to confirm the proposed device and the current patient labeling. If the device changes later, request a new explanation of the relevant differences before treating the earlier discussion as complete.

For monitoring, describe the plan in a sentence with an action and a responsible clinician or service. “Future scans” leaves the timing, arrangement and payment questions open. Instead, record what the team actually recommends, who will arrange it and what remains to be confirmed. Keep the recommendation distinct from any appointment you have already attended. This helps the breast augmentation care record remain accurate over time.

For costs, imagine receiving a separate bill after surgery. Which written term would establish whether that service was included? Check the quote rather than relying on memory. Mark an unknown charge as unknown and request clarification; do not add a speculative amount to make the breast augmentation budget look finished. If financing is offered, keep the payment agreement alongside the clinical quote so that repayment terms are not mistaken for included care.

Finally consider a change of practice or home address. Would you know where to find your device card, operative details, instructions and imaging reports? Decide how you will retain copies and which contact details will need updating. This is an information-management plan, not an alternative to clinical follow-up. It is particularly useful because the breast augmentation decision involves responsibilities after the initial operation as well as the appearance goal that brought you to the consultation.

ASPS notes that visible size change is immediate while appearance continues to settle as swelling changes; incision appearance can evolve over a longer period. It also describes ongoing changes related to aging, weight and other factors. Those processes are reasons to discuss assessment timing rather than judge the final result from the first photograph. ASPS result and follow-up information.

Return to the goals in your original record. Ask how each is being assessed and whether a concern needs examination. Distinguish an appearance preference from a symptom or a device-integrity question so the clinician can address the right task. Keep new findings dated without rewriting the original goals after the fact.

For breast augmentation, the decision is stronger when you can explain the proposed treatment, its limits, the device information, the monitoring discussion and the financial commitments in your own words. If any part remains unclear, ask for another explanation before deciding. The site’s breast lift guide, procedure library and general questions page provide related starting points for that conversation.